Novo Nordisk A/S shares fell the most since December after the drugmaker’s next-generation shot CagriSema showed 15.7% weight ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Obesity is a major global health issue, increasing the risk of heart disease, diabetes, and high blood pressure. Despite many ...

Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...

STORY: Shares of Novo Nordisk tumbled 10% Monday morning after the drugmaker revealed weaker-than-expected data about its ...

Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in ...

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

The obesity study that disappointed ... raising concern among investors that the new medicine might not be differentiated enough against what’s already a blockbuster drug, said Michael Shah ...